StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
EVH$4.18+0.00%
Fair $4.18+0.0%

EVH

Evolent Health, Inc.

Healthcare / Health Information ServicesNYSE

$4.18

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $4.18Fund rank 26/100 · Data gapFallback financials|
SA 7/F
F-Score: 2/9
High DebtLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF n/d · quality 42.0/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 50/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

7/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 13Warnings: 2unknown: 13
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 2.34, above the 2.0 threshold ROE is -1.3%, below the 5% threshold
Thesis & Journal · EVHLocal privado en este navegador · Evolent Health, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$470M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-128.7%

↓

Gross Margin

N/A

•

Debt/Equity

2.34

↑
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2013–2025 · 12 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

—

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.88B · net income $-534.5M · FCF —

2013-FY → 2025-FY

Gross margin

—— pts

Operating margin

-21.9%— pts

Net margin

-28.5%— pts

FCF margin

—— pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Income Statement
Revenue$1.88B$1.88B$2.55B$1.96B$1.35B$908.0M$924.6M$846.4M$627.1M$434.9M$254.2M———
Net Income$-534.5M$-534.5M$-61.6M$-113.0M$-19.2M$-37.6M$-334.2M$-302.0M$-52.7M$-60.7M$-159.7M$332.5M$-25.2M$20.0M
EBITDA$-294.3M$-294.3M$77.9M$52.2M$70.8M$17.6M$-201.4M$-248.0M$-3.0M$-40.5M$-220.2M$-35.8M$0.00$-19.9M
EPS-5.07-5.07-0.81-1.28-0.20-0.44-3.94-3.67—-0.94-3.556.93-13.460.99
Operating Margin-21.9%-21.9%-1.6%-3.6%0.3%-4.7%-28.4%-36.5%-7.6%-16.7%-93.4%———
Net Margin-28.5%-28.5%-2.4%-5.8%-1.4%-4.1%-36.1%-35.7%-8.4%-13.9%-62.8%———
Balance Sheet
Debt/Equity2.342.340.490.560.480.310.430.320.190.120.170.00——
Cash Flow
Free Cash Flow———————$-78.2M$-60.2M$-55.8M$-51.0M$-25.0M$0.00$-24.1M
Returns
ROE-128.7%-128.7%-6.2%-10.6%-2.2%-5.4%-53.9%-32.5%-4.6%-6.0%-22.7%51.2%1219.6%—
Growth & Yield
Revenue Growth-26.6%-26.6%30.1%45.3%48.9%-1.8%9.2%35.0%44.2%71.1%————
EPS Growth-525.9%-525.9%36.7%-540.0%54.5%88.8%-7.4%——73.5%-151.2%151.5%-1459.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.